The status of paediatric medicines initiatives around the world—what has happened and what has not?
- 779 Downloads
This review was conducted to examine the current status of paediatric medicines initiatives across the globe.
The authors made a non-systematic descriptive review of current world situation.
Two regions, the United States (US) and the European Union (EU), and the World Health Organization (WHO) have introduced strong paediatric initiatives to improve children’s health through improving access to better paediatric medicines. The experience from the US initiative indicates that it is possible to stimulate development and study of paediatric medicines and provide important new information for improvement of paediatric therapy. The early results from the EU initiative are similarly encouraging. In Canada, Japan, Australia and other developed countries, specific paediatric medicines initiatives have been less extensive and weaker, with modest results. Disappointingly, current evidence suggests that results from clinical trials outside the US often do not benefit children in the country in which the trials were largely conducted. Pharmaceutical companies that have derived a financial benefit commensurate with the cost of doing the paediatric trials in one country do not seem to be making the results of these trials available to all countries if there is no financial incentive to the company. The WHO campaign ‘make medicines child size’ has produced substantive accomplishments in building improved foundations to improve mechanisms that will enhance children’s access to critical medicines in resource-limited settings. However, practically all of this work has been performed using an amalgamation of short-term funding from a variety of sources as opposed to a sustained, programmatic commitment.
Although much still needs to be done, it’s clear that with concerted efforts and appropriate resources, change is possible but slow. Retaining and fostering public and political interest in paediatric medicines is challenging, but pivotal for success.
KeywordsBiomedical research Legislation Jurisprudence Child Drugs, investigational
We thank Professor Gita Batmanabane, India, for providing information on the situation in India. Dr Kalle Hoppu and Dr Hidefumi Nakamura are members of the Global Research in Paediatrics (GRIP) consortium which has received research funding from the European Union 7th Framework Program.
- 2.World Health Assembly (2007) Resolution WHA60.20 ‘Better medicines for children’Google Scholar
- 5.US FDA (2003) Pediatric Research Equity Act. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM077853.pdf
- 6.European Commission (2006) Regulation (EC) no 1901/2006 of the European parliament and of the Council on medicinal products for paediatric use and amending Regulation (EEC) no 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 (2006). http://ec.europa.eu/health/files/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf
- 10.US FDA Office of Pediatric Therapeutics (2011) Breakdown of FDAAA completed pediatric studies. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm190622.htm. Accessed 20 January 2011
- 11.Baker-Smith CM, Benjamin DK Jr, Grabowski HG, Reid ED, Mangum B, Goldsmith JV, Murphy MD, Edwards R, Eisenstein EL, Sun J, Califf RM, Li JS (2008) The economic returns of pediatric clinical trials of antihypertensive drugs. Am Heart J 156(4):682–688. doi: 10.1016/j.ahj.2008.05.001 PubMedCrossRefGoogle Scholar
- 12.European Medicines Agency (2010) European Medicines Agency receives 1,000th application for a Paediatric Investigation Plan or Waiver. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/10/news_detail_001128.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1. Accessed 29 November 2010
- 13.European Medicines Agency (2010) Report to the European Commission. http://ec.europa.eu/health/files/paediatrics/article_50_report2010.pdf. Accessed 19 January 2011
- 15.Drug Therapy Committee of the Japan Pediatric Society (2000) Survey of the current state of pediatric drug use in Japan (1994–6). Pediatr Int 42 (1):109–113Google Scholar
- 17.Department of Health and Ageing (2008) National medicines policy advisory structures and priorities. http://www.commcarelink.health.gov.au/internet/main/publishing.nsf/Content/nmp-advisory-structure.htm. Accessed 6 December 2010
- 19.Department of Health and Ageing (2008) Paediatric medicines advisory group. http://www.commcarelink.health.gov.au/internet/main/publishing.nsf/Content/nmp-pmag. Accessed 6 December 2010
- 20.Hoppu K, Sri Ranganathan S, Dodoo ANO (2011) Realities of paediatric pharmacotherapy in the developing world. Arch Dis Child. doi: 10.1136/adc.2009.180000
- 21.Pan American Health Organization (2010) Network for drug regulatory harmonization website. http://new.paho.org/hq/index.php?option=com_content&task=blogcategory&id=1156&Itemid=513. Accessed 8 December 2010
- 22.PANDRH GPC committee (2008) V Pan American conference on drug regulatory harmonization: preliminary report, conclusions and recommendations. http://new.paho.org/hq/dmdocuments/2009/V-Conf-PANDRH_Draft-Reportr.pdf. Accessed 8 December 2010
- 23.PANDRH GPC Committee (2008) PANDRH good clinical practices workgroup—draft under discussion—guide for conducting clinical studies in pediatric populations. http://new.paho.org/hq/dmdocuments/2008/VConferencePANDRH_4_ClinicalPractices.pdf. Accessed 8 December 2010
- 24.Pan American Health Organization (no year) Guia para realizacion de ensayos clinicos en poblacion pediatrica—borrador en discusion. http://www.anmat.gov.ar/publicaciones/BPC-Investpediatrica.pdf. Accessed 8 December 2010
- 25.WHO (2007) WHO global campaign: make medicines child size. http://www.who.int/childmedicines/en/index.html. Accessed 7 January 2011
- 26.World Health Organization (2008) The selection and use of essential medicines. Report of the WHO Expert Committee, October 2007 (including the Model List of Essential Medicines for Children). Technical report series, vol 950. WHO, GenevaGoogle Scholar
- 27.World Health Organization (2009) The selection and use of essential medicines. Report of the WHO Expert Committee, 2009 (including the 16th WHO Model List of Essential Medicines and the 2nd WHO Model List of Essential Medicines for Children), Technical report series, vol 958. WHO, GenevaGoogle Scholar
- 29.Hoppu K, Hogerzeil HV (2011) Global aspects of drug development. In: Seyberth H, Rane A, Schwab M (eds) Handbook of experimental pharmacology, vol 205. Pediatric clinical pharmacology. Springer, BerlinGoogle Scholar
- 30.WHO (2010) WHO model formulary for children 2010. WHO, GenevaGoogle Scholar
- 31.WHO (2010) Report of WHO second partners meeting on better medicines for children (Geneva, October 2010). http://www.who.int/entity/childmedicines/progress/partners_meeting_2010.pdf. Accessed 7 January 2011
- 32.WHO (2008) WHO report of the informal expert meeting on dosage forms of medicines for children. http://www.who.int/childmedicines/progress/Dosage_form_reportDEC2008.pdf
- 33.Ministry of Healthcare and Nutrition and Department of Pharmacology (2006) National list of essential medicines, Sri Lanka, 3rd revisionGoogle Scholar
- 34.Ministry of Healthcare and Nutrition and Department of Pharmacology (2009) National list of essential medicines, Sri Lanka, 4th revisionGoogle Scholar
- 36.National Institutes of Health (2010) Pediatric trials network. http://bpca.nichd.nih.gov/clinical/network/index.cfm. Accessed 4 December 2010
- 37.European Medicines Agency (2011) European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA). http://www.ema.europa.eu/ema/index.jsp?curl=pages/partners_and_networks/general/general_content_000303.jsp&murl=menus/partners_and_networks/partners_and_networks.jsp&mid=WC0b01ac05801df74a. Accessed 10 January 2011
- 38.European Medicines Agency (2011) Enpr-EMA membership. http://www.ema.europa.eu/ema/index.jsp?curl=pages/partners_and_networks/q_and_a/q_and_a_detail_000108.jsp&jsenabled=true. Accessed 10 January 2011
- 39.Maternal, Infant, Child and Youth Research Network (MICYRN) (2011) Home page. www.micyrn.ca. Accessed 10 January 2011
- 40.Department of Innovation, Industry, Science and Research (2011) Clinical Trials Action Group (CTAG). http://www.innovation.gov.au/Industry/PharmaceuticalsandHealthTechnologies/ClinicalTrialsActionGroup/Pages/default.aspx. Accessed 19 January 2011
- 41.US NIH (2010) ClinicalTrials.gov. www.clinicaltrials.gov. Accessed 8 December 2010
- 43.Drugs for Neglected Diseases Initiative (2010) Home page. http://www.dndi.org/. Accessed 8 December 2010
- 44.TDR (2011) Research on neglected priority needs. http://apps.who.int/tdr/svc/research. Accessed 19 January 2011
- 45.Manikandan S, Jayanthi M, Sivagnanam G (2011) Clinical trials in children: an assessment of the information in the Clinical Trials Registry of India (CTRI). Indira Gandhi Medical College & Research Institute, PondicherryGoogle Scholar
- 46.European Commission, DG Enterprise (2004) Extended impact assessment. http://ec.europa.eu/enterprise/sectors/pharmaceuticals/files/paediatrics/docs/extended_impact_assessment_final_3_september_en.pdf. Accessed 19 January 2011
- 49.US FDA (2011) Pediatric exclusivity granted. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM223058. Accessed 20 January 2011
- 55.WHO/UNAIDS/UNICEF (2010) Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. http://www.who.int/hiv/pub/2010progressreport/report/en/index.html%22%20%5Ct%20%22_blank. Accessed 15 November 2010